Neurologic disease and brain trauma affect the lives of over 100 million patients in the US alone, accounting for over $1.3 trillion of nondiscretionary healthcare spending every year. Unfortunately, this market is challenged by failed drug trials, ineffective treatments, and delayed diagnoses. A critical missing piece is the lack of low-cost blood testing products that can be used as tools to enable breakthrough discoveries in research and drug development in these important diseases.
Accelerating Breakthrough Discoveries in Brain Disease and Health
ZelosDx is the first company to mine the debris found in a phagocyte white blood cell for evidence of brain damage or repair. ZelosDx discovered and developed the WINDOW INTO THE BRAIN TM blood testing system that can be used by pharmaceutical companies as tools for drug discovery and by researchers conducting studies in brain disease. Our blood tests offer a novel approach (single cell analysis vs serum), a simple, minimally invasive (small amounts of blood), and significantly cheaper (than existing) assay systems. More successful studies and drug trials produce more effective treatments.
While the initial focus of ZelosDx was on MS, where neuroinflammation is a well-researched aspect of this disease, it is becoming clear that inflammation plays a central role in brain injury and disease. The WINDOW INTO THE BRAINTM is a platform technology that can be used to test human and animal model blood samples across several neurodegenerative diseases such as Multiple Sclerosis, Parkinson’s, Alzheimer’s and TBI. With the aging demographics in the US and other developed countries the monitoring of brain health with a simple blood test would be of tremendous health and financial benefit to the patient as well as the society at large.